ANDROID 25 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Android 25, and when can generic versions of Android 25 launch?
Android 25 is a drug marketed by Valeant Pharm Intl and is included in one NDA.
The generic ingredient in ANDROID 25 is methyltestosterone. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methyltestosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Android 25
A generic version of ANDROID 25 was approved as methyltestosterone by IMPAX LABS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ANDROID 25?
- What are the global sales for ANDROID 25?
- What is Average Wholesale Price for ANDROID 25?
Summary for ANDROID 25
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 57 |
| Clinical Trials: | 10 |
| Patent Applications: | 4,013 |
| DailyMed Link: | ANDROID 25 at DailyMed |
Recent Clinical Trials for ANDROID 25
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| St. Olavs Hospital | Phase 4 |
| Oslo University Hospital | Phase 4 |
| Haukeland University Hospital | Phase 4 |
US Patents and Regulatory Information for ANDROID 25
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Pharm Intl | ANDROID 25 | methyltestosterone | TABLET;ORAL | 087147-001 | Approved Prior to Jan 1, 1982 | BP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
